Ivosidenib and Ruxolitinib in Patients With Advanced Blood Cancers That Have IDH1 Gene MutationPhase MPNs

Conditions: Myeloproliferative Neoplasms Interventions: Drug: Ivosidenib; Drug: Ruxolitinib Sponsors: University of Chicago Not yet recruiting

Source: ClinicalTrials.gov - March 4, 2024 Category: Research Source Type: clinical trials